icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
RK3HgnXFP3S88QP1
Listen
